The characteristics of the sample are presented in Table 1 and Table 2. The average age was 60.9 years, and patients had been diagnosed an average of 12 years. Most were male (81%), and 38% were ...

Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...

Pegloticase quickly resolved tophi among patients with gout who responded to the treatment, according to data published in Arthritis Research & Therapy. “Pegloticase is a recombinant mammalian uricase ...

Please provide your email address to receive an email when new articles are posted on . Both excessive and long-term alcohol consumption, as well as any spirit consumption, predict the development of ...

US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is ...

Krystexxa, a PEGylated uric acid specific enzyme, is approved for the treatment of refractory chronic gout. One study retrospectively analyzed data from two 6-month, randomized clinical trials that ...

Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was associated ...

Bone erosions, which are associated with long-term damage and disability, are common in patients with gout and have been linked with specific clinical and ultrasound-detected factors, Chinese ...

In one of these studies, the new product, called AR882 for the time being, reduced serum urate by 40% to 60% in dose-dependent fashion over a 12-week treatment period, whereas a placebo group showed ...

Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...